Reviewing Titan Medical (NASDAQ:TMDIF) and T2 Biosystems (NASDAQ:TTOO)

Valuation and Earnings

This table compares Titan Medical and T2 Biosystems”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63 million	2.02	$6.95 million	$0.05	6.25
T2 Biosystems	$7.68 million	0.03	-$50.08 million	N/A	N/A

Titan Medical has higher revenue and earnings than T2 Biosystems.

Risk and Volatility

Titan Medical has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500.

Institutional & Insider Ownership

0.0% of Titan Medical shares are owned by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are owned by institutional investors. 0.0% of Titan Medical shares are owned by insiders. Comparatively, 0.0% of T2 Biosystems shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Titan Medical and T2 Biosystems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
T2 Biosystems	-563.16%	N/A	-174.06%

Summary

Titan Medical beats T2 Biosystems on 6 of the 9 factors compared between the two stocks.

About Titan Medical

Titan Medical Inc. operates as a medical technology company. It focuses on the development and licensing of robotic assisted surgical technologies. The company is headquartered in Toronto, Canada.

About T2 Biosystems

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.